2019
Multi-Institutional Validation of Deep Learning for Pretreatment Identification of Extranodal Extension in Head and Neck Squamous Cell Carcinoma.
Kann BH, Hicks DF, Payabvash S, Mahajan A, Du J, Gupta V, Park HS, Yu JB, Yarbrough WG, Burtness BA, Husain ZA, Aneja S. Multi-Institutional Validation of Deep Learning for Pretreatment Identification of Extranodal Extension in Head and Neck Squamous Cell Carcinoma. Journal Of Clinical Oncology 2019, 38: 1304-1311. PMID: 31815574, DOI: 10.1200/jco.19.02031.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaExtranodal extensionSquamous cell carcinomaLymph nodesCell carcinomaContrast-enhanced CT scanDiagnostic abilityBoard-certified neuroradiologistsTreatment escalationCancer Genome AtlasPathologic confirmationPretreatment identificationDiagnostic challengeExternal validation data setsPathology resultsPretreatment imagingPoor prognosticatorClinical utilityCT scanPatientsClinical decisionHNSCCDiagnostic accuracyInstitutional ValidationGenome Atlas
2017
NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis
Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA. NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis. Nature Communications 2017, 8: 1772. PMID: 29176703, PMCID: PMC5701248, DOI: 10.1038/s41467-017-01877-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCohort StudiesFemaleGene Expression Regulation, NeoplasticHistone MethyltransferasesHistone-Lysine N-MethyltransferaseHumansIntracellular Signaling Peptides and ProteinsLaryngeal NeoplasmsMaleMiddle AgedMutationNuclear ProteinsPrognosisRepressor ProteinsSquamous Cell Carcinoma of Head and NeckConceptsUseful clinical metricSquamous cell carcinomaLaryngeal cancer patientsPoor overall survivalIndependent validation cohortDistinct prognostic outcomesMolecular prognostic biomarkersOverall survivalCancer Genome AtlasFavorable prognosisBetter prognosisValidation cohortCell carcinomaCancer patientsLaryngeal tumorsLaryngeal cancerPrognostic outcomesTreatment stratificationPrognostic biomarkerNasal cavityOral cavityHigh recurrenceAnatomical sitesPatient stratificationCancer subtypesTRAF3/CYLD mutations identify a distinct subset of human papillomavirus‐associated head and neck squamous cell carcinoma
Hajek M, Sewell A, Kaech S, Burtness B, Yarbrough WG, Issaeva N. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus‐associated head and neck squamous cell carcinoma. Cancer 2017, 123: 1778-1790. PMID: 28295222, PMCID: PMC5419871, DOI: 10.1002/cncr.30570.Peer-Reviewed Original ResearchConceptsHPV-positive HNSCCNeck squamous cell carcinomaDe-escalation therapyHPV-positive HNSCCsMechanisms of HPVRecurrent metastatic diseaseBetter overall survivalSquamous cell carcinomaNuclear factor-κB signalingFactor-κB signalingNew therapeutic strategiesNuclear factor κBHPV vaccineCancer Genome AtlasCurative optionHPV statusMetastatic diseaseOverall survivalCervical cancerPatient survivalSmoking characteristicsCell carcinomaHuman papillomavirusLifelong morbidityClinical trials